MetaVia is trading 6.34% higher at $1.43 on October 9, 2026; no verified company-specific announcement explaining the move was identified, leaving the reason uncertain.
- Its investor-relations releases list the September 9 preclinical update as the latest release.
- The broader market is higher, but supplied index changes are below the stated 0.5% threshold and do not establish a clear market-wide explanation.